Evidence map›Paper›PMID 21730841›Full record

ReviewCurrent opinion in ophthalmology2011

The pathophysiology of thyroid eye disease: implications for immunotherapy.

Raymond S Douglas, Shivani Gupta

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in ophthalmology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02316691 (B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease), which is not on this map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02316691 terminatednot on this mapstarted 2016, after this paper: background citation

B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease

TypeobservationalSponsorUniversity of PittsburghRan2016 to 2019Enrolled2ConditionsThyroid Eye Disease
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Raymond S DouglasThyroid Eye Disease Center at the Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan 48105, USA. raydougl@med.umich.edu
Shivani Gupta
University of Michigan–Ann Arbor · US

Funding

The role of CD40+ fibrocytes in thyroid associated ophthalmopathyR01EY021197 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DOUGLAS, RAYMOND S · 2011 to 2015
$1.9M
NEI NIH HHS R01 EY021197PHS HHS R01 EYO21197
6 · The paper itself

Abstract

purpose of reviewThyroid eye disease (TED) is a poorly understood autoimmune manifestation most commonly associated with Graves' disease. Current nonspecific treatment paradigms offer symptomatic improvement but fail to target the underlying pathogenic mechanisms, and thus do not significantly alter the long-term disease outcome. The purpose of this review is to provide an update of the current understanding of the immunopathogenesis of TED and explore these mechanisms for targeted immunotherapy. RECENT

findingsOrbital fibroblasts are integral to the pathogenesis of TED and may modulate immune responses by production of cytokines and hyaluronan in response to activation of shared autoantigens including thyrotropin receptor and insulin-like growth factor-1 receptor. Bone marrow-derived fibrocytes share many of these phenotypic and functional features, suggesting a link between systemic and site-specific disease. Use of targeted immunotherapies in TED is limited, though data from the use Rituximab (RTX), a B-cell depleting agent, are encouraging. Sustained clinical response has been seen with RTX in several reports, despite return of peripheral B-cell levels to pretreatment levels. Additionally, this response appears to be independent of cytokine and antibody production, suggesting modulation of antigen presentation as a mechanism of its effect. SUMMARY: Progressive advances in the understanding of the immunopathogenesis of TED continue to spur clinical trials utilizing targeted immune therapies. Continued understanding of the molecular mechanisms of disease will expand potential treatments for TED patients and obviate the need for reconstructive surgical therapies.

Indexed as

ImmunotherapyAutoantigensDisease ProgressionFemaleGraves OphthalmopathyHumansMalePhenotypeReceptors, ThyrotropinT-LymphocytesAutoantigensReceptors, Thyrotropin

Identifiers

PMID21730841
PMCPMC3512192
OpenAlexW2024130220

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.